Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial - Long, G V; Atkinson, V; Cebon, J S (Lancet Oncol, 2017)
et al.